CANCER:

Thyroid Gland Medullary Carcinoma

Related cancers:

‹

Thyroid Gland Carcinoma (322)

Thyroid Gland Anaplastic Carcinoma (57)

Thyroid Gland Papillary Carcinoma (49)

Thyroid Gland Follicular Carcinoma (24)

Thyroid Gland Hurthle Cell Carcinoma (12)

Thyroid Gland Carcinoma (322)

Thyroid Gland Anaplastic Carcinoma (57)

Thyroid Gland Papillary Carcinoma (49)

Thyroid Gland Follicular Carcinoma (24)

Thyroid Gland Hurthle Cell Carcinoma (12)

›

No biomarker No biomarker	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval
No biomarker No biomarker	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval
No biomarker No biomarker	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	denosumab Sensitive: A2 - Guideline
No biomarker No biomarker	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib tablet Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pembrolizumab Sensitive: A2 - Guideline
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline
KRAS mutation KRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline
NRAS mutation NRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline
HRAS mutation HRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	TPX 0046 Sensitive: C2 – Inclusion Criteria
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	BOS-172738 Sensitive: C2 – Inclusion Criteria
RET V804* RET V804*	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials
RET C634* RET C634*	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C3 – Early Trials
RET C634R RET C634R	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C3 – Early Trials
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C3 – Early Trials
RET V804M RET V804M	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials
RET V804L RET V804L	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C3 – Early Trials
RET V804M + RET M918T + RET G810 + RET Y806 RET V804M + RET M918T + RET G810 + RET Y806	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Resistant: C4 – Case Studies
NF1 mutation NF1 mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies
ATM S978fs12 ATM S978fs12	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies
ATM L804fs4 ATM L804fs4	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	everolimus + vandetanib Sensitive: C4 – Case Studies
RET C620R RET C620R	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	everolimus Sensitive: C4 – Case Studies
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	everolimus Sensitive: C4 – Case Studies
RET C618R RET C618R	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C4 – Case Studies
RET C634F RET C634F	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: C4 – Case Studies
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies
ATM S978fs12 ATM S978fs12	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies
ATM L804fs4 ATM L804fs4	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: C4 – Case Studies
RET L629P RET L629P	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C4 – Case Studies
RET D631_R635delinsG RET D631_R635delinsG	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C4 – Case Studies
RET V637R RET V637R	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: C4 – Case Studies
RET exon 11 deletion RET exon 11 deletion	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sorafenib + tipifarnib Sensitive: C4 – Case Studies
RET V804M + M918T RET V804M + M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C4 – Case Studies
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sunitinib Sensitive: C4 – Case Studies
RET Y900_S904delinsP RET Y900_S904delinsP	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: C4 – Case Studies
CCDC6-ALK fusion CCDC6-ALK fusion	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	alectinib Sensitive: C4 – Case Studies
RET C634W RET C634W	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RAF265 Sensitive: D – Preclinical
RET M918T RET M918T	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	AMG 706 Resistant: D – Preclinical
RET C634W RET C634W	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	AMG 706 Resistant: D – Preclinical
RET C634W RET C634W	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	lenvatinib Sensitive: D – Preclinical
KRAS G12R KRAS G12R	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
BRAF mutation BRAF mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
PTEN mutation PTEN mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
RET mutation RET mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
NRAS mutation NRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
KRAS mutation KRAS mutation	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	RTB101 + RAF265 Sensitive: D – Preclinical
RET C634W RET C634W	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: D – Preclinical
BRAF V600E BRAF V600E	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	CI-1040 Sensitive: D – Preclinical
RET C634Y RET C634Y	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	sorafenib Sensitive: D – Preclinical

Thyroid Gland Medullary Carcinoma

Associations(55)

Associations
(55)